O2 affects the activity of amikacin on mycobacterium abscessus biofilm by Kolpen, M. et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 20, 2017
O2 affects the activity of amikacin on mycobacterium abscessus biofilm
Kolpen, M.; Ravnholt, C.; Qvist, T.; Kragh, Knud Abildgaard; Fritz, B.; Bjarnsholt, T.; Høiby, N.; Jensen,
P.
Published in:
Pediatric Pulmonology
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Kolpen, M., Ravnholt, C., Qvist, T., Kragh, K. A., Fritz, B., Bjarnsholt, T., ... Jensen, P. (2017). O2 affects the
activity of amikacin on mycobacterium abscessus biofilm. Pediatric Pulmonology, 52(Suppl. S47), 359-360.
Poster Session Abstracts
359
Conclusions: This study suggests that piperacillin-tazobactam therapy 
in combination with tobramycin in pediatric CF patients may cause a great-
er incidence of AKI when compared to cefepime.
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LASR REGULATES PSEUDOMONAS AERUGINOSA-
MEDIATED NEUTROPHIL EXTRACELLULAR TRAP 
FORMATION
Skopelja-Gardner, S.; Theprungsirikul, J.; Hammond, J.; 
Lewis, K.; Hogan, D.A.; Rigby, W. Microbiology and 
Immunology, Geisel School of Medicine at Dartmouth, Hanover, 
NH, USA
Introduction:Pseudomonas aeruginosa is a major pulmonary pathogen 
in cystic fibrosis (CF), associated with increased morbidity and mortal-
ity. P. aeruginosa utilizes different mechanisms to colonize CF airways 
despite host immune responses. Mutations in the quorum sensing regula-
tory gene lasR confer a survival advantage to P. aeruginosa and appear 
to impart increased pathogenicity in CF patients. The mechanism(s) by 
which LasR-deficient P. aeruginosa evades neutrophil-mediated bacteri-
cidal functions is unknown. Neutrophil extracellular trap (NET) formation 
(NETosis) is an important antimicrobial mechanism. The objective of this 
study is to understand the role of LasR in P. aeruginosa-mediated NETosis.
Methods: Purified human neutrophils from healthy donors were treated 
for 2h at 37°C with PMA (100nM) or different MOIs (1, 10, and 100) of 
P. aeruginosa strains: wild-type (wt), LasR-deficient (DlasR), LasB-de-
ficient (DlasB), PqsR-deficient (DpqsR), RhlR-deficient (DRhlR), LasR/
PqsR-deficient (DlasRDpqsR), and LasR/RhlR-deficient (DlasRDRhlR). 
The extracellular release of host DNA was quantified by Sytox Green (5 
μM) and fluorescence measurement (485/530nm). The role of LasB and 
LasA in LasR regulated NETosis was examined using recombinant proteins 
or by pre-treatment of P. aeruginosa wt with elastase inhibitor tropolone 
(0-1mM). The NADPH oxidase-dependence of NETosis was determined 
by comparing the inhibition of diphenyleneiodonium chloride (DPI;10 μM) 
and subsequent treatment with P. aeruginosa. Data are represented as per-
cent maximum DNA release of 0.5% TritonX treated PMNs. NETs and 
distribution of NET proteins were evaluated by immunocytochemistry.
Results: Relative to wt, LasR-deficient P. aeruginosa strains were 
markedly deficient in inducing NETs despite comparable motility and 
lipopolysaccharide expression levels. This effect of LasR-deficiency on 
NETosis occurred independently of downstream quorum sensing signaling 
pathways. Rather, LasR-dependent transcriptional induction of Pseudomo-
nas elastase LasB and Pseudomonas protease LasA appeared to account for 
the increased NETosis triggered by wild type, relative to LasR-deficient P. 
aeruginosa strains. Finally, we observed phenotypic differences between 
NETs stimulated by LasR-sufficient and LasR-deficient P. aeruginosa 
strains.
Conclusions: This study demonstrates, for the first time, that LasR is 
an essential regulator of Pseudomonas aeruginosa-mediated NETosis. This 
effect is independent of the downstream quorum sensing pathways and 
results from decreased expression of virulence factors LasB and LasA in 
the absence of LasR. Together, our findings uncover a novel role for LasR 
in regulating neutrophil function, which could have important implications 
in the adaptability of this pathogen to innate immune defenses.
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GENE-SILENCING ANTISENSE OLIGOMERS: A NOVEL 
THERAPEUTIC APPROACH TO COMBAT MULTIDRUG 
RESISTANT PSEUDOMONAS AERUGINOSA IN VITRO 
AND IN VIVO
Moustafa, D.A.1,2; Zamora, D.3; Daly, S.4; Sturge, C.4; 
Geller, B.5; Goldberg, J.1,2; Greenberg, D.3,4 1. Department of 
Pediatrics, Division of Pulmonology, Allergy/Immunology, 
Cystic Fibrosis and Sleep, Emory University, Atlanta, GA, USA; 
2. Emory-Children’s Center For Cystic Fibrosis Research, Emory 
University and Children’s Health Care of Atlanta, Atlanta, GA, 
USA; 3. Department of Internal Medicine, University of Texas 
Southwestern Medical Center, Dallas, TX, USA; 4. Department of 
Microbiology, University of Texas Southwestern Medical Center, 
Dallas, TX, USA; 5. Department of Microbiology, Oregon State 
University, Corvallis, OR, USA
Cystic fibrosis (CF) is a genetic and progressive disease of significant 
health concern and is often complicated by chronic infection with the highly 
virulent, multidrug-resistant Pseudomonas aeruginosa. Given the dramat-
ically increasing rate of multidrug resistance among CF patients, urgent 
and novel approaches to therapeutics are needed. We utilize antisense tech-
nology, specifically peptide-conjugated phosphorodiamidate morpholino 
oligomers (PPMOs), designed to inhibit mRNA translation of specific 
essential genes in P. aeruginosa and other gram-negative bacteria. We have 
previously demonstrated the efficacy of P. aeruginosa PPMOs targeted to 
essential genes, such as acpP (acyl carrier protein), lpxC (UDP-(3-O-acyl)-
N-acetylglucosamine deacetylase), and rpsJ (30S ribosomal protein S10), 
in inhibiting growth and biofilm in vitro. Additionally a single, delayed 
intranasal treatment was shown to significantly reduce the lung bacterial 
burden in a murine acute pneumonia model. Here we expand upon these 
data to show that combinations of PPMOs and clinically relevant antibiotics 
act synergistically in reducing existing biofilms of P. aeruginosa. Further-
more, multiple delayed intranasal treatments with AcpP, LpxC, or RpsJ 
PPMOs within 6-24 hours post-infection results in significantly improved 
survival of mice compared to controls. In vivo imaging (IVIS) during these 
experiments further verified the bactericidal effect of the PPMO treatments. 
These data suggest that PPMOs alone or in combination with antibiotics 
represent a novel approach to address the problems associated with rapidly 
increasing antibiotic resistance in P. aeruginosa.
379
O2 AFFECTS THE ACTIVITY OF AMIKACIN ON 
MYCOBACTERIUM ABSCESSUS BIOFILM
Kolpen, M.4; Ravnholt, C.1,2; Qvist, T.3; Kragh, K.5; Fritz, B.5; 
Bjarnsholt, T.5; Høiby, N.3,5; Jensen, P.3,5 1. Rigshospitalet, 
Copenhagen, Denmark; 2. Department of System Biology, 
Technical University of Denmark, Lyngby, Denmark; 
3. Department of Infectious Diseases, Rigshospitalet, 
Copenhagen, Denmark; 4. Department of Clinical Microbiology, 
Rigshospitalet, Copenhagen, Denmark; 5. Costerton Biofilm 
Center, Department of Immunology and Microbiology, Faculty 
of Health and Medical Sciences, University of Copenhagen, 
Copenhagen, Denmark
Nontuberculous mycobacteria, notably the multi-resistant Mycobac-
terium abscessus (MABSC), are ubiquitous environmental organisms that 
frequently cause difficult-to-treat chronic lung infections in cystic fibrosis 
patients (CF). MABSC infections in CF lungs are difficult to successful-
ly treat, due to their natural resistance towards most clinically available 
antibiotics. MABSC biofilms have been observed in CF lung sputum where 
oxygen (O2) consumption caused by polymorphonuclear leukocyte activi-
ty creates anaerobic conditions. Accumulating evidence suggests that the 
efficacy of several bactericidal antibiotics, such as aminoglycosides, is 
enhanced by stimulation of pathogens’ aerobic respiration and decreased by 
lack of O2. Current experiments aim to elucidate the role of cell aggregation 
(biofilms) and study the bactericidal killing of MABSC by amikacin during 
aerobic and anaerobic conditions.
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Inoculums from 5-day-old cultures of MABSC isolates from CF 
patients grown in Mueller Hinton broth with 5% Tween 80 (MH) were 
added to aerobic and anaerobic MH media in 20 mL glass vials to achieve 
105 cells/mL. Samples were sealed with parafilm or an airtight lid and incu-
bated at 37oC, 150 rpm. Samples with various concentrations (%) of Tween 
80 were evaluated by confocal laser scanning microscopy on a Zeiss LSM 
880 confocal microscope running Zen 2.1 together as well as by micro-res-
pirometry of O2. Time-kill curves were generated for amikacin treatment in 
four-fold dilutions from 2 to 512 mg/mL. The number of bacterial colony 
forming units (CFU) was determined after 1, 3 and 5 days of incubation.
Conclusion: Bacterial disaggregation increased amikacin efficacy 
suggesting that aggregation contributes to antibiotic tolerance in a fash-
ion similar to other biofilm infections. Low O2 consumption in MABSC 
aggregates creates slow-growing or dormant subpopulations, which are 
protected against amikacin activity. The bactericidal activity of amikacin 
may be increased by restoring aerobic conditions in sputum, e.g. through 
hyperbaric oxygen therapy.
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ROLE OF PARANASAL SINUSES IN EARLY  
P. AERUGINOSA INFECTION IN CF
Dolce, D.1; Ravenni, N.1; Campana, S.1; Camera, E.1; 
Castellani, C.2; Braggion, C.1; Taccetti, G.1 1. Cystic Fibrosis 
Centre, Department of Pediatric Medicine, Anna Meyer 
Children’s University Hospital, Florence, Italy; 2. Rehabilitation 
Unit, Anna Meyer Children’s University Hospital, Florence, Italy
Introduction: Chronic Pseudomonas aeruginosa (P. aeruginosa) lung 
infections are the major cause of morbidity and mortality in cystic fibrosis 
(CF) patients. A major purpose of treating patients is to prevent or delay 
chronic P. aeruginosa lung infections. During the initial phase of lung 
infection, bacteria can be treated with early eradication therapy. Following 
eradication, lung re-infection can occur due to bacteria with the identical 
genotype as the previous infection. This may be due to re-colonization from 
the patient’s paranasal sinuses. Although the CFTR defect affects respirato-
ry cells in the upper airways (UA) and lower airways (LA) equally, routine 
microbiological assessment of the UA is not part of standard care.
Aims: The aims of the study were to evaluate, using non-invasive meth-
ods, the microbiological status of the UA of CF patients not chronically 
infected with P. aeruginosa. Genotyping of P. aeruginosa strains from the 
UA and LA were also performed in order to assess if the UA may represent 
a re-infection source.
Methods: During the period 2014-2017, 40 patients not chronically 
infected by P. aeruginosa, according to the Leeds’ definition, were evalu-
ated. We simultaneously sampled the LA and UA: the LA by expectorated 
sputum or deep throat swab and the UA by nasal lavage, using the Mainz 
method (Mainz JG, et al. Thorax 2009;64:535-40). P. aeruginosa strains of 
all positive samples were genotyped by BOX-PCR.
Results: A total of 49 nasal lavages and concomitant LA specimens 
were analyzed from 40 patients (age 2-43 years, median 13 years). During 
the study period 9 out of 49 (18.4%) nasal lavage and 21 (42.9%) LA were 
found positive for P. aeruginosa. From simultaneously collected positive 
samples, 7 out of 9 specimens (77.7%) carried identical P. aeruginosa gen-
otypes in the UA and LA. P. aeruginosa isolates from UA were susceptible 
to the majority of tested antibiotics: 90% of isolates was susceptible to 
tobramycin, ciprofloxacin, piperacillin-tazobactam, ticarcillin-clavulanic 
acid and imipenem, 80% to cefepime, 70% to amikacin, 60% to genta-
micin and 50% to levofloxacin. No resistance to colistin, meropenem or 
ceftazidime was found. Only one P. aeruginosa isolate showed a mucoid 
phenotype.
Conclusions: The presence of identical genotypes in the UA and 
LA suggests that the UA play a role in the acquisition and persistence of 
P. aeruginosa in CF. Nasal lavage appears to be suitable for non-invasive 
UA sampling even though microbiological assessment of the UA is not 
currently considered part of the standard care of CF patients. Since the 
P. aeruginosa strains isolated from the UA had low antibiotic resistance, the 
efficacy of antibiotic treatment of the paranasal sinuses should be evaluated. 
In summary, upper airway involvement in CF is undertreated and requires 
prospective investigation and an interdisciplinary consensus on diagnosis 
and therapy.
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INFECTION PREVENTION AND CONTROL (IP&C) 
RECOMMENDATIONS AT CF CENTERS IN THE 
UNITED STATES
Saiman, L.1; Maykowski, P.1; Zhou, J.J.1; Stoudemire, W.2; 
Jiang, X.2; Kosorok, M.2; Muhlebach, M.S.2 1. Columbia Univ., 
New York, NY, USA; 2. Univ. of North Carolina, Chapel Hill, 
NC, USA
Objective: We sought to determine if IP&C recommendations made in 
both the 2003 and 2013 IP&C Guidelines would more likely be included in 
current IP&C policies than recommendations first made in 2013.
Methods: From 12/2015 to 6/2016, CF care centers’ program directors 
provided researchers with their written IP&C policies for CF. Inpatient and 
outpatient policies that were institutionally approved or awaiting approval 
and those created by the CF care teams without ‘’official” approval were 
each reviewed by two researchers for selected recommendations made in 
the 2003 and/or 2013 Guideline (Table). The percent of policies with spe-
cific 2003 and/or 2013 recommendations for inpatient and outpatient set-
tings was determined and compared.
Results: Among the 280 CF care centers, 144 responded; 14 replied 
they had no written policies, or policies without mention of CF; 130 (46%) 
provided written IP&C policies. Written policies were provided by 38 
(29%) adult, 74 (57%) pediatric and 18 (14%) affiliate centers. The percent 
of centers with policies that contained specific inpatient and outpatient 
recommendations is shown (Table). When compared to recommendations 
made in both 2003 and 2013, new 2013 recommendations were more like-
ly included in policies for inpatient settings (p=0.02) than for outpatient 
settings (p=0.07). The most common recommendations included 2013 rec-
ommendations for mask use by patients and Contact Precautions for all 
patients in both inpatient and outpatient settings (Bonferroni correction, all 
p<0.05). A few centers’ policies included practices not recommended, i.e., 
mask use by staff for all patients, or unresolved, i.e., airborne isolation for 
non-tuberculous mycobacteria (NTM).
Conclusions: Among responding centers, mask use by patients and 
Contact Precautions were rapidly implemented suggesting high rates of 
acceptance for the use of personal protective equipment. A few centers’ 
policies included not recommended or unresolved practices, suggesting that 
local experience may guide IP&C recommendations. Future studies should 
assess the impact of specific IP&C practices at CF care centers.
Supported by CF Foundation.
 Percentage of CF Care Centers with Selected IP&C Recommenda-
tions Currently in Place
NA=not applicable
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